FierceBiotech Mar 6, 2026 FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
FierceBiotech Mar 6, 2026 Beam rejigs deal to retain base editing technology amid partner's dissolution
FierceBiotech Mar 6, 2026 Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda
FierceBiotech Mar 6, 2026 Senior FDA official refutes uniQure's claims amid controversy over Huntington's gene therapy
FierceBiotech Mar 6, 2026 Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
FierceBiotech Mar 6, 2026 Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug
FierceBiotech Mar 5, 2026 Alltrna undergoes third layoff round before entering clinic, cutting 35% of jobs
FierceBiotech Mar 5, 2026 Daiichi Sankyo pens pact with Germany's Gaia to sell digital therapeutic for high cholesterol
FierceBiotech Mar 4, 2026 Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'
FierceBiotech Mar 4, 2026 Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations